Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 2, pp 161–163

VIM-D salvage chemotherapy in Hodgkin's disease

Authors

  • Julia K. Phillips
    • Department of HaematologyRoyal Liverpool Hospital
  • Ruth L. Spearing
    • Department of HaematologyRoyal Liverpool Hospital
  • John M. Davies
    • Department of HaematologyRoyal Liverpool Hospital
  • Charles R. M. Hay
    • Department of HaematologyRoyal Liverpool Hospital
  • Huw Parry
    • Department of HeamatologyYsbyty Gwynedd, Penrhosgarnedd
  • John R. Nash
    • Department of HistopathologyRoyal Liverpool Hospital
Original Articles Salvage Chemotherapy, Hodgkin's Disease

DOI: 10.1007/BF00689103

Cite this article as:
Phillips, J.K., Spearing, R.L., Davies, J.M. et al. Cancer Chemother. Pharmacol. (1990) 27: 161. doi:10.1007/BF00689103

Summary

A total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16), ifosfamide, mitozantrone and dexamethasone (VIM-D). The regime was well tolerated, the only major toxicity being myelosuppression. Complete remissions (CRs) were obtained in 4 patients and were maintained for 2,4, 10 and 14 months, 10 subjects subsequently received an autologous bone marrow transplant with highdose chemotherapy (ABMT). Previous exposure to VIMD did not appear to predict for or prejudice the response to subsequent ABMT.

Copyright information

© Springer-Verlag 1990